We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
CAT No: CP27560
CAS No: 878797-09-2
Synonyms/Alias: 878797-09-2;Fmoc-Tyr(tBu)-Ser(Psi(Me,Me)pro)-OH;Fmoc-Tyr(Tbu)-Ser(Psime,Mepro)-OH;FMOC-TYR(TBU)-SER(PSI-ME,MEPRO)-OH;(4S)-3-[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoyl]-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid;(4S)-3-(Fmoc-Tyr(tBu))-2,2-dimethyl-oxazolidine-4-carboxylic acid;(S)-3-((S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(tert-butoxy)phenyl)propanoyl)-2,2-dimethyloxazolidine-4-carboxylic acid;Fmoc-Tyr(tBu)-Ser[Psi(Me, Me)Pro]-OH;MFCD11974986;HY-P2387;AKOS025289498;AS-62069;DA-53368;FF111366;CS-0133726;Fmoc-L-Tyr(tBu)-L-Ser(Psi(Me,Me)pro)-OH;S-878797-09-2;(4S)-3-[(2S)-3-[4-(tert-butoxy)phenyl]-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanoyl]-2,2-dimethyl-1,3-oxazolidine-4-carboxylic acid;(4S)-3-[(2S)-3-[4-(TERT-BUTOXY)PHENYL]-2-{[(9H-FLUOREN-9-YLMETHOXY)CARBONYL]AMINO}PROPANOYL]-2,2-DIMETHYL-1,3-OXAZOLIDINE-4-CARBOXYLIC ACID;(S)-3-((S)-2-(((E)-((9H-fluoren-9-yl)methoxy)(hydroxy)methylene)amino)-3-(4-(tert-butoxy)phenyl)propanoyl)-2,2-dimethyloxazolidine-4-carboxylic acid;(S)-3-(N-alpha-(9-Fluorenylmethyloxycarbonyl)-O-t-butyl-L-tyrosinyl)-2,2-dimethyloxazolidine-4-carboxylic acid;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C34H38N2O7 |
M.W/Mr. | 586.7 |
Size | 1 g;5 g; |
InChI | InChI=1S/C34H38N2O7/c1-33(2,3)43-22-16-14-21(15-17-22)18-28(30(37)36-29(31(38)39)20-42-34(36,4)5)35-32(40)41-19-27-25-12-8-6-10-23(25)24-11-7-9-13-26(24)27/h6-17,27-29H,18-20H2,1-5H3,(H,35,40)(H,38,39)/t28-,29-/m0/s1 |
InChI Key | DNJYPUYQFPFOKS-VMPREFPWSA-N |
Canonical SMILES | CC1(N(C(CO1)C(=O)O)C(=O)C(CC2=CC=C(C=C2)OC(C)(C)C)NC(=O)OCC3C4=CC=CC=C4C5=CC=CC=C35)C |
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com